This question is part of our collaboration with ACR Convergence 2025 to preview a session from this year's meeting. This question is inspired by the upcoming session "GLP1 Agonists in Rheumatic Disease and Osteoarthritis: Should We Give Them to Everyone?" by Dr. C. Thomas Appleton and Dr. Francis Berenbaum.